Milestone Pharmaceuticals Inc.
NASDAQ:MISTBiotechnology
Healthcare
$0.46 -0.01%
-$0.00 today
- Market cap
- $57.32M
- Beta
- 0.96
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$0.52
52W Low $1.00High $3.06
Volume 2.23M
Average 1.99M
Income Statement
Follow revenue through to earnings.
Revenue
$1.55M
FY 2025 · Annual
Operating Income
-$62.48M
FY 2025 · Annual
Net Income
-$63.06M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 15M | 5M | 1M | 0 | 1.55M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 114K |
| Gross Profit | 15M | 5M | 1M | 0 | 1.43M |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | 92.6% |
| Research & Development | 38.67M | 39.83M | 31.05M | 14.36M | 18.11M |
| Selling, General & Admin | 19.4M | 24.81M | 31.05M | 27.75M | 17.27M |
| Operating Expenses | 58.07M | 64.64M | 62.1M | 42.1M | 63.92M |
| Depreciation & Amortization | 93K | 89K | 92K | 105K | 114K |
| EBITDA | (42.76M) | (58.3M) | (57.04M) | (37.83M) | (59.45M) |
| EBITDA Margin | -285.1% | -1166.0% | -5703.9% | — | -3845.5% |
| Operating Income | (43.07M) | (59.64M) | (61.1M) | (42.1M) | (62.49M) |
| Operating Margin | -287.2% | -1192.8% | -6109.8% | — | -4041.7% |
| Interest Income | 220K | 1.25M | 3.97M | 4.16M | 2.92M |
| Interest Expense | 0 | 0 | 2.55M | (3.58M) | 3.84M |
| Other Income / Expenses | 220K | 1.25M | 1.41M | 583K | (918K) |
| Income Before Tax | (42.85M) | (58.39M) | (59.69M) | (41.52M) | (63.4M) |
| Pre-Tax Margin | -285.7% | -1167.8% | -5968.5% | — | -4101.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | (345K) |
| Net Income | (42.85M) | (58.39M) | (59.69M) | (41.52M) | (63.06M) |
| Net Margin | -285.7% | -1167.8% | -5968.5% | — | -4078.8% |
| EPS (Basic) | (1.02) | (1.35) | (1.39) | (0.67) | (0.75) |
| EPS (Diluted) | (1.02) | (1.35) | (1.39) | (0.67) | (0.75) |
| 41.83M | 42.45M | 42.96M | 62.21M | 83.88M | |
| 41.83M | 42.45M | 42.96M | 62.21M | 83.88M |
MIST Earnings Waterfall · TTM
NASDAQ:MIST · Revenue to Net Income
Key Ratios
EPS$-0.68
Gross Margin42.6%
Net Margin-3019.5%
P/E Ratio-2.3
P/S Ratio190.3
Analysis
$1.8M of revenue converted into -$68.4M of net income for the selected period. Gross margin is 42.6% and net margin is -3019.5%, showing how much revenue survives after costs and taxes. EPS is $-0.68, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 13, 2026 | |
| 8-K | Current report | Nov 13, 2026 | |
| 8-K | Current report | Oct 28, 2026 | |
| 8-K | Current report | Sep 3, 2026 | |
| 8-K | Current report | Aug 12, 2026 |
How much revenue does MIST generate?
Milestone Pharmaceuticals Inc. (MIST) reported $1.55M of revenue in fiscal 2025.
Is MIST profitable?
Milestone Pharmaceuticals Inc. (MIST) reported -$63.06M of net income, with a net margin of -4078.8%.
Continue the stock analysis
Jump to another research area for this company.